Balaji Amines Q1 FY27: PAT jumps 114%, margins up

Key takeaway from the quarter

Balaji Amines reported a strong start to FY27, with revenue growth and a sharp improvement in profitability metrics during the quarter ended June 30, 2026. The company’s operating performance improved meaningfully as EBITDA more than doubled year-on-year and margins expanded versus both the year-ago period and the previous quarter. Profit after tax (PAT) also rose sharply on a year-on-year basis, reflecting higher operating leverage.

The results were approved by the Board of Directors on July 27, 2026, as part of the company’s compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The same set of disclosures also referenced improved capacity utilisation and cost absorption as the newly commissioned Dimethyl Ether (DME) plant begins scaling.

Revenue growth led by operations

Revenue from operations in Q1 FY27 rose to ₹455.92 crore, up 27.23% year-on-year from ₹358.34 crore. Total revenue stood at ₹461.44 crore, a 25.61% increase from ₹367.36 crore in Q1 FY26. On a sequential basis, revenue from operations increased from ₹394.78 crore in Q4 FY26, while total revenue was up from ₹402.51 crore.

Some excerpts in the provided material also presented revenue values in lakh terms, including a reference to consolidated revenue from operations of ₹4,559.2 lakh (₹455.92 crore) and total income of ₹4,614.5 lakh (₹461.45 crore, rounded). The quarter’s key numbers were consistently communicated as being in the ₹456 crore to ₹461 crore range.

EBITDA more than doubles; margin expansion stands out

EBITDA (excluding other income) came in at ₹115.87 crore in Q1 FY27, registering 111.87% year-on-year growth from ₹54.69 crore. Compared with ₹94.24 crore in Q4 FY26, EBITDA increased 22.95% quarter-on-quarter. The operating margin expansion was equally notable.

EBITDA margin stood at 25.41% in Q1 FY27. This compared with 15.26% in Q1 FY26 and 23.87% in Q4 FY26, translating to an improvement of 10.15 percentage points year-on-year and 1.54 percentage points quarter-on-quarter. The company’s commentary in the provided text attributed margin gains to improved capacity utilisation and better cost absorption, with the DME plant beginning to scale.

PAT jumps; EPS nearly doubles YoY

Profit after tax (PAT) for Q1 FY27 was reported at ₹78.12 crore, up 113.79% from ₹36.54 crore in Q1 FY26. Sequentially, PAT rose 20.61% from ₹64.77 crore in Q4 FY26. PAT margin also improved to 17.13% versus 10.20% a year ago and 16.41% in the previous quarter.

Earnings per share (EPS) increased to ₹23.13 from ₹11.73 in Q1 FY26, marking 97.19% year-on-year growth. EPS also improved quarter-on-quarter from ₹19.99 in Q4 FY26, an increase of 15.71%.

The broader write-up included multiple profit figures for the same quarter in different summaries, including a mention of consolidated Q1 FY27 profit of ₹74.9 crore and another line citing consolidated net profit of ₹78.1 crore. The detailed quarterly table in the material, however, presented PAT at ₹78.12 crore.

Standalone and consolidated snapshots mentioned

Beyond the main quarterly table, the text also cited standalone and consolidated performance points. It stated that standalone revenue was ₹422.74 crore with profit of ₹72.14 crore in Q1 FY27, and that standalone revenue rose from ₹319.38 crore in Q1 FY26 to ₹422.74 crore in Q1 FY27, while standalone profit increased from ₹39.80 crore to ₹72.14 crore.

Another section described the company’s standalone status as zero-debt. The same collection of notes also described Balaji Amines as a leading Indian manufacturer of aliphatic amines and specialty chemicals, and said it has four manufacturing sites (three near Solapur and one near Hyderabad), alongside a hotel operation in Solapur.

Table: reported quarterly performance (as provided)

What the disclosures suggest about operational drivers

The margin and profit expansion in Q1 FY27 was linked in the provided text to improved capacity utilisation and cost absorption. The scaling up of the DME plant was specifically cited as a contributor to operating efficiency in the quarter. While revenue grew at a healthy pace, the much faster growth in EBITDA and PAT indicates a quarter where incremental revenues translated into materially higher operating profit.

In the same set of notes, the company’s revenue growth was described as being supported by higher volumes and pricing in its core amines business. Separately, one snapshot included a sales volume figure of 21,587 MT for Q1 FY27 and 27,570 MT for Q1 FY26, alongside a standalone sales volume of 20,619 MT for Q1 FY27.

Dividend and reported market snapshot points

The material also noted that the company declared a dividend of Rs 11 per equity share for the financial year ended March 31, 2026, at its 38th AGM held on July 10, 2026. A separate market snapshot in the text referenced the stock trading at a P/E of 33.1 and a market capitalisation of ₹5,528, alongside a price point of ₹1,822.

Outlook references included in the material

The provided content included management expectations around volume growth. It stated a target of around 25% to 30% volume growth by the end of FY27 compared to current levels, and also referenced expectations of 20% to 30% volume growth in FY27, driven by plants such as DME, Acetonitrile, and N-Methyl Morpholine (NMM), and demand from battery industries.

Conclusion

Balaji Amines’ Q1 FY27 performance was defined by a strong rise in revenue alongside a sharp improvement in operating profitability, with EBITDA margin expanding to 25.41% and PAT rising to ₹78.12 crore. The company’s board approved the quarterly results on July 27, 2026, and the quarter’s narrative in the provided text linked margin gains to improved utilisation and the scaling of the DME plant. Investors will track subsequent quarters for how these utilisation benefits and the company’s stated volume growth targets translate into sustained operating metrics.